GlassScriptPhysician profile
James Grant Howard
NPI 1255711453
$1,363.55
in general payments reported to CMS, 2019-2025
25 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.51 · 2020: $56.33 · 2021: $193 · 2022: $192 · 2023: $275 · 2024: $232 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $326.78 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $192.75 | 2019-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $145.70 | 2019-2025 | Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.36 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $73.91 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $70.13 | 2020-2022 | |
| Glaxosmithkline, LLC. | $52.29 | 2019-2023 | Bexsero |
| Dynavax Technologies Corporation | $36.61 | 2025 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.23 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $31.84 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.47 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $28.59 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2021-2023 | Jardiance |
| Verona Pharma, INC. | $22.76 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $22.73 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $21.36 | 2022 | |
| Genentech USA, INC. | $20.96 | 2022 | |
| Shield Therapeutics INC | $20.54 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.18 | 2021 | |
| Redhill Biopharma INC. | $17.75 | 2020 | |
| Abbott Laboratories | $17.41 | 2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $15.46 | 2022 | |
| Amgen INC. | $13.87 | 2024 | Prolia, Evenity |
| E.R. Squibb & Sons, L.L.C. | $12.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.